Tetje Cornelia van der Sluis

Tetje Cornelia van der Sluis

Auto-generated profile, based on publicly available information

Tetje Cornelia van der Sluis

Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2023 in Nature
Verified
Journal Article
Open access
PDF file
BKBastian Kruse
Bastian Kruse
ABAnthony C. Buzzai
Anthony C. Buzzai
NSNaveen Shridhar
Naveen Shridhar
ABAndreas D. Braun
Andreas D. Braun
SGSusan Gellert
Susan Gellert
TTThomas Tüting
Thomas Tüting
Most clinically applied cancer immunotherapies rely on the ability of CD8+ cytolytic T cells to directly recognize and kill tumour cells1–3. These strategies are limited by the emergence of major histocompatibility complex (MHC)-deficient tumour cells and the formation of an immunosuppressive tumour microenvironment4–6. The ability of CD4+ effector cells to contribute to antitumour immunity independently of CD8+ T cells is increasingly recognized, but strategies to unleash their full potential remain to be identified7–10. Here, we describe a mechanism whereby a small number of CD4+ T cells is sufficient to eradicate MHC-deficient tumours that escape direct CD8+ T cell targeting. The CD4+ effector T cells preferentially cluster at tumour invasive margins where they interact with MHC-II+CD11c+ antigen-presenting cells. We show that T helper type 1 cell-directed CD4+ T cells and innate immune stimulation reprogramme the tumour-associated myeloid cell network towards interferon-activated antigen-presenting and iNOS-expressing tumouricidal effector phenotypes. Together, CD4+ T cells and tumouricidal myeloid cells orchestrate the induction of remote inflammatory cell death that indirectly eradicates interferon-unresponsive and MHC-deficient tumours. These results warrant the clinical exploitation of this ability of CD4+ T cells and innate immune stimulators in a strategy to complement the direct cytolytic activity of CD8+ T cells and natural killer cells and advance cancer immunotherapies.

1 October 2017 in Immunity
Verified
Journal Article
Closed access
NGNicole Glodde
Nicole Glodde
TBTobias Bald
Tobias Bald
DBDebby van Den Boorn-Konijnenberg
Debby van Den Boorn-Konijnenberg
KNKyohei Nakamura
Kyohei Nakamura
JOJake S. O’donnell
Jake S. O’donnell
MHMichael Hölzel
Michael Hölzel

13 April 2016 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MWMarij J. Welters
Marij J. Welters
TSTetje C. van der Sluis
Tetje C. van der Sluis
HMHélène van Meir
Hélène van Meir
NLNikki M. Loof
Nikki M. Loof
VHVanessa J. van Ham
Vanessa J. van Ham
Sjoerd H. van der BurgSjoerd H. van der Burg
Sjoerd H. van der Burg
Therapeutic vaccination against HPV16 is effective with chemotherapy for advanced cervical cancer patients.

1 October 2013 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MFMarieke F. Fransen
Marieke F. Fransen
TSTetje C. van der Sluis
Tetje C. van der Sluis
FOFerry Ossendorp
Ferry Ossendorp
RARamon Arens
Ramon Arens
CMCornelis J.M. Melief
Cornelis J.M. Melief
Purpose: Blockade of CTLA-4 by antibodies has potentiated antitumor T-cell responses in both preclinical models and clinical trials. However, treatment with CTLA-4 blocking antibodies is associated with autoimmune and inflammatory side effects. In this study, we propose a novel administration method for CTLA-4 blocking antibodies as monotherapy. Experimental Design: We use different preclinical mouse models of cancer to investigate the local administration of CTLA-4 blocking antibody and its effect on cancer progression and the antitumor T-cell response. Results: By injecting the antibodies in a subcutaneous slow-release delivery formulation in the tumor area, we show that an eight-fold lower dose of antibody is as effective in inducing tumor eradication as systemic delivery. A lower dose and slow release of the antibody results in thousand-fold decreased levels of antibody in the serum, reducing adverse events and the risk of autoimmunity. The main target and effector cells of the CTLA-4 blockade treatment in the studied tumor models are tumor-specific endogenous CD8+ T cells that are capable of eradicating also distant tumors, whereas CD4+ T cells do not play a prominent role in the antibody-mediated tumor eradication. Conclusions: Injecting CTLA-4 blocking antibody in a slow-release formulation close to the tumor is an effective way of activating the antitumor T-cell response. This administration method is associated with very low serum levels of antibody, which decreases the risk of treatment-induced side effects. These results call for exploration of a similar delivery principle in clinical settings. Clin Cancer Res; 19(19); 5381–9. ©2013 AACR.

13 October 2016 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ENElham Beyranvand Nejad
Elham Beyranvand Nejad
TSTetje C. van der Sluis
Tetje C. van der Sluis
SDSuzanne van Duikeren
Suzanne van Duikeren
HYHideo Yagita
Hideo Yagita
GJGeorge M. Janssen
George M. Janssen
RARamon Arens
Ramon Arens
Certain cytotoxic chemotherapeutic drugs are immunogenic, stimulating tumor immunity through mechanisms that are not completely understood. Here we show how the DNA-damaging drug cisplatin modulates tumor immunity. At the maximum tolerated dose (MTD), cisplatin cured 50% of mice with established murine TC-1 or C3 tumors, which are preclinical models of human papillomavirus (HPV)-associated cancer. Notably, the curative benefit of cisplatin relied entirely upon induction of tumor-specific CD8+ T cells. Mechanistic investigations showed that cisplatin stimulated tumor infiltration of inflammatory antigen-presenting cells (APC) expressing relatively higher levels of the T-cell costimulatory ligands CD70, CD80, and CD86. Cell death triggered by cisplatin was associated with the release of at least 19 proteins in the tumor environment that could act as damage-associated molecular patterns and upregulate costimulatory molecules, either alone or in concert, but the responsible proteins remain unknown. Essentially, the curative effect of cisplatin was abrogated in mice lacking expression of CD80 and CD86 on APCs. Furthermore, cisplatin treatment was improved by CTLA-4 blockade, which increases the availability of CD80/86 to bind to CD28. In contrast, there was no effect of CD27 stimulation, which replaces CD70 interaction. At the cisplatin MTD, cure rates could also be increased by vaccination with synthetic long peptides, whereas cures could also be achieved at similar rates at 80% of the MTD with reduced side effects. Our findings reveal an essential basis for the immunogenic properties of cisplatin, which are mediated by the induction of costimulatory signals for CD8+ T-cell–dependent tumor destruction. Cancer Res; 76(20); 6017–29. ©2016 AACR.

15 February 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
TSTetje C. van der Sluis
Tetje C. van der Sluis
SDSuzanne van Duikeren
Suzanne van Duikeren
SHSuzanna Huppelschoten
Suzanna Huppelschoten
Ekaterina S. JordanovaEkaterina S. Jordanova
Ekaterina S. Jordanova
ENElham Beyranvand Nejad
Elham Beyranvand Nejad
CMCornelis J.M. Melief
Cornelis J.M. Melief
Purpose: Cancer immunotherapy, such as vaccination, is an increasingly successful treatment modality, but its interaction with chemotherapy remains largely undefined. Therefore, we explored the mechanism of synergy between vaccination with synthetic long peptides (SLP) of human papillomavirus type 16 (HPV16) and cisplatin in a preclinical tumor model for HPV16. Experimental Design: SLP vaccination in this preclinical tumor model allowed the elucidation of novel mechanisms of synergy between chemo- and immunotherapy. By analyzing the tumor immune infiltrate, we focused on the local intratumoral effects of chemotherapy, vaccination, or the combination. Results: Of several chemotherapeutic agents, cisplatin synergized best with SLP vaccination in tumor eradication, without requirement for the maximum-tolerated dose (MTD). Upon SLP vaccination, tumors were highly infiltrated with HPV-specific, tumor necrosis factor-α (TNFα)- and interferon-γ (IFNγ)–producing T cells. Upon combined treatment, tumor cell proliferation was significantly decreased compared with single treated and untreated tumors. Furthermore, we showed that TNFα strongly enhanced cisplatin-induced apoptotic tumor cell death in a JNK-dependent manner. This is consistent with upregulation of proapoptotic molecules and with enhanced cell death in vivo upon combined SLP vaccination and cisplatin treatment. In vivo neutralization of TNFα significantly reduced the antitumor responses induced by the combined treatment. Conclusion: Taken together, our data show that peptide vaccination with cisplatin treatment leads to decreased tumor cell proliferation and TNFα-induced enhanced cisplatin-mediated killing of tumor cells, together resulting in superior tumor eradication. Clin Cancer Res; 21(4); 781–94. ©2014 AACR.